DUBLIN, Oct. 27, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global H1N1 Vaccines Market 2014-2018" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
H1N1 influenza (zoonotic) is an infectious disease in humans caused by a variant of the swine H1N1 virus, known as H1N1v virus. The H1N1v virus is a contagious virus which infects nose, throat, and lungs. H1N1 virus is an RNA virus belonging to the Orthomyxoviridae family. Influenza A viruses infect different animal species such as humans, swine, birds, seals, and horses. Influenza A viruses can be subdivided on the basis of antigenicity of its surface glycoproteins neuraminidase and hemagglutinin.
Hemagglutinin component is used by the virus to bind to host cell receptors. This facilitates viral entry into the host cell. Neuraminidase protein enzymatically cleaves terminal sialic acid residues from mucins, thereby allowing the virus to reach underlying cells in the respiratory tract.
Elderly people, young children, and people with medical conditions including liver disorders, blood disorders, kidney disorders, chronic lung disease, asthma, and neurodevelopmental and neurological conditions are at a higher risk of getting infected. Influenza vaccines are administered for active immunization against influenza virus. This, in turn, confers protection against influenza disease. Vaccination of high-risk groups prevents unnecessary hospitalizations and premature deaths resulting due to influenza.
The analysts forecast the Global H1N1 Vaccines market to grow at a CAGR of 5.40 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global H1N1 Vaccines market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of various vaccines administered to prevent human infection caused by H1N1 virus.
The report, the Global H1N1 Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global H1N1 Vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
One of the upcoming trends in the market is the emergence of quadrivalent vaccines as they confer additional protection. In February 2012, the FDA approved FluMist Quadrivalent, the first quadrivalent vaccine in the US. It was approved in the EU in December 2013 as Fluenz Tetra.
According to the report, the increase in awareness about the disease is a major driver of the market. Lack of awareness about the infection, its implications, and available vaccines increases the chances of developing an infection. Hence, the increase in awareness is expected to increase the targeted population for vaccination.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Market Segmentation by Route of Administration
08. WHO Recommendation
09. Key H1N1 Virus Vaccines for the 2013-2014 Season in the US
10. H1N1 Virus Vaccines Approved in the EU
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
20. Key Vendor Analysis
21. Other Reports in this Series
Companies Mentioned:
- AstraZeneca
- GlaxoSmithKline
- Novartis
- Sanofi Pasteur
- Baxter International
- bioCSL
- Mitsubishi Tanabe Pharma
- Protein Sciences Corporation
- Serum Institute of India
- Sinovac Biotech
- Zydus Cadila
For more information visit http://www.researchandmarkets.com/research/5s7gcr/global_h1n1
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
